Yazar "Sevindik, Ömür Gökmen" için listeleme
-
Acute lymphoblastic leukemia in routine practice: A Turkish multicenter study
Çiftçiler, Rafiye; Sevindik, Ömür Gökmen; Tekgündüz, Ali İrfan Emre; Erkurt, Mehmet Ali; Vural, Filiz; Turgut, Burhan; Kaynar, Leylagül; Payzın, Bahriye; Doğu, Mehmet Hilmi; Karakuş, Volkan; Altuntaş, Fevzi; Büyükaşık, Yahya; Demirkan, Fatih (Turkish Society of Hematology, 2019)Objective: Significant developments occurred in the clinical management of acute lymphoblastic leukemia (ALL) in adults in recent decades. However, treatment results are still not satisfactory, especially in routine practice. ... -
Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO)
Sevindik, Ömür Gökmen; Gemici, Aliihsan; Usta, Furkan Selim; Çakır, Aslı; Sadri, Sevil; Bekoz, Hüseyin; Sargın, Fatma Deniz (The American Society of Hematology, 2019)Gemtuzumab Ozogamycin (GO) is a drug conjugated monoclonal antibody which targets CD33 an antigen highly expressed on the surface of AML blasts. GO is approved for the treatment of both newly-diagnosed and relapsed AML. ... -
Akut miyeloid lösemi tanılı hastalarda remisyon indüksiyon kemoterapisi döneminde primer antifungal profilaksi alan ve almayan hastaların retrospektif olarak değerlendirilmesi
Mutlay, Feyza; Sevindik, Ömür Gökmen; Solmaz, Şerife; Acar, Celal; Alpçavuş, Sema; Seyhanlı, Ahmet; Özcan, Mehmet Ali; Demirkan, Fatih; Özsan, Güner Hayri; Ündar, Bülent; Alacacıoğlu, İnci (Lösemi Lenfoma Miyelom Derneği, 2020)Amaç: Akut miyeloid lösemi (AML) hastalarında gelişen invaziv fungal enfeksiyonlar (İFE)mortalitenin en önemli nedeni olarak görülmektedir. İFE gelişimi için yüksek riskli dönem olanindüksiyon tedavisi döneminde hastalara ... -
Artificial intelligence to assist better myeloma care, is it the time?
Sevindik, Ömür Gökmen (Cıg Media Group, 2019)Myeloma treatment made an enormous progress during the last decade. Armamentarium is grossly enlarging each year in the field of treatment. Parallel to the progress achieved to provide better care for myeloma patients, ... -
Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort
Mutlu, Yaşa Gül; Güvenç, Birol; Serin, İstemi; Balık Aydın, Berrin; Alacacıoğlu, İnci; Güven, Serkan; Sevindik, Ömür Gökmen (American Society of Hematology, 2022)Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' ... -
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
Sevindik, Ömür Gökmen; Chen, Chang; Yang, Jing; Farooqui, Mohammed Z. H.; Paszkiewicz-Kozik, Ewa (Lippincott Williams & Wilkins, 2023)... -
Can neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio at day+100 be used as a prognostic marker in multiple myeloma patients with autologous transplantation?
Solmaz Medeni, Şerife; Acar, Celal; Olgun, Aybüke; Acar, Alev; Seyhanlı, Ahmet; Taşkıran, Emin; Sevindik, Ömür Gökmen; Alacacıoğlu, İnci; Pişkin, Özden; Özcan, Mehmet Ali; Demirkan, Fatih; Ündar, Bülent; Özsan, Güner Hayri (Blackwell Publishing Ltd, 2018)Background: Recent reports have showed that neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) are predictors of progression-free survival (PFS) and overall ... -
Can procalcitonin levels differentiate gram-negative bacteremia from gram-positive bacteremia?
Olmuşçelik, Oktay; Yılmaz, Mesut; Sevindik, Ömür Gökmen; Tosun İstanbullu, Ayşe; Ceylan, Ecem Cemre; Güler, Ayşenur; Vardar, Büşra (2019)Objective: Patients with sepsis constitute a significant proportion of critically ill patients. Although outcomes have significantly improved in the last decade, mortality still remains high 25-30% and 40-50% when shock ... -
A case series of CML patients who were presented with isolated thrombocytosis
Karakuş, Volkan; Aslan, Vedat; Parça, Güleycan; Sevindik, Ömür Gökmen; Keklik Karadağ, Fatma; Kurtoğlu, Erdal; Saydam, Güray (American Society of Hematology, 2022)Per WHO 2016 and 2022 (5th ed.) myeloproliferative disease guidelines, Chronic Myeloid Leukemia (CML) is classified under two major groups according to the presence of bcr-abl translocation; these groups require different ... -
Clinical characteristics and outcomes of COVID-19 in Turkish patients with hematological malignancies
Civriz Bozdağ, Sinem; Cengiz Seval, Güldane; Yönal Hindilerden, İpek; Hindilerden, Fehmi; Andıç, Neslihan; Baydar, Mustafa; Aydın Kanyar, Lale; Toprak, Selami Koçak; Göksoy, Hasan Sami; Balık Aydın, Berrin; Demirci, Ufuk; Can, Ferda; Özkocaman, Vildan; Gündüz, Eren; Güven, Zeynep Tuğba; Özkurt, Zübeyde Nur; Demircioğlu, Sinan; Beksaç, Meral; İnce, İdris; Yılmaz, Umut; Eroğlu Küçükdiler, Hilal; Abishov, Elgün; Yavuz, Boran; Ataş, Ünal; Mutlu, Yaşa Gül; Baş, Volkan; Özkalemkaş, Fahir; Üsküdar Teke, Hava; Gürsoy, Vildan; Çelik, Serhat; Çiftçiler, Rafiye; Yağcı, Münci; Topçuoğlu, Pervin; Çeneli, Özcan; Abbasov, Hamza; Selim, Cem; Ar, Muhlis Cem; Yücel, Orhan Kemal; Sadri, Sevil; Albayrak, Canan; Demir, Ahmet Muzaffer; Güler, Nil; Keklik, Muzaffer; Terzi, Hatice; Doğan, Ali; Yegin, Zeynep Arzu; Kurt Yüksel, Meltem; Sadri, Soğol; Yavaşoğlu, İrfan; Beköz, Hüseyin Saffet; Aksu, Tekin; Maral, Senem; Erol, Veysel; Kaynar, Leylagül; İlhan, Osman; Bolaman, Ali Zahit; Sevindik, Ömür Gökmen; Akyay, Arzu; Özcan, Muhit; Gürman, Günhan; Ünal, Şule; Yavuz, Yasemin; Diz Küçükkaya, Reyhan; Özsan, Güner Hayri (NLM (Medline), 2022)Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly ... -
Clinical outcomes and treatment patterns of primary central nervous system lymphoma: Multicenter retrospective analysis
Güven, Serkan; Yavuz, Boran; Erdoğan Yücel, Elçin; Karataş, Aylin Fatma; Özsan, Güner Hayri; Demirkan, Fatih; Ündar, Bülent; Özcan, Mehmet Ali; Kiper, Hatice Demet; Çetintepe, Tuğba; Göçer, Mesut; Kurtoğlu, Erdal; Balık Aydın, Berrin; Sevindik, Ömür Gökmen; Yiğit Kaya, Süreyya; Alacacıoğlu, İnci (Kare Publishing, 2023)Objectives: Primary central nervous system lymphoma (PCNSL) is a rare malignant disease with poor prognosis. Its low incidence leads to challenges in decision-making for treatment. As a matter of fact, there is still no ... -
Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients
Sevindik, Ömür Gökmen; Bilgen, Hülya; Serin, İstemi; Melek, Elif; Karakuş, Volkan; Çerçi, Kübra; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Sadri, Sevil; Beköz, Hüseyin Saffet; Kaynar, Leylagül (American Society of Hematology, 2022)Introduction The commonest indication for an Autologous Stem Cell Transplantation (ASCT) is still Multiple Myeloma. A successful mobilization of hematopoietic stem cells (HSC) is a sine qua non of ASCT. The introduction ... -
Comparison of outcomes of total body irradiation (TBI) vs non-TBI conditioning regimens in acute lymphoblastic leukemia for allogeneic transplantation
Beköz, Hüseyin Saffet; Sevindik, Ömür Gökmen; Özçelik, Tülay; Arat, Mutlu; Hindilerden, İpek Yonal; Beşışık, Sevgi Kalayoğlu; Nalcacı, Meliha; Uzay, Ant; Kartı, Süleyman Sami; Kıvanç, Demet; Sargın, Deniz (Nature Publishing Group, 2019)... -
Correlation between serum vitamin D level and dichotomous distribution of hematological parameters in a cohort of 12709 patients
Olmuşçelik, Oktay; Sevindik, Ömür Gökmen (Tübitak Scientific & Technical Research Council Turkey, 2020)Background/aim: Recent evidence suggests that Vitamin D deficiency may be associated with varying degrees of peripheral blood cytopenia(s). However, the effect of Vitamin D on hematopoiesis is largely unknown. According ... -
The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma
Solmaz, Şerife; Uzun, Özcan; Sevindik, Ömür Gökmen; Demirkan, Fatih; Özcan, Mehmet Ali; Özsan, Güner Hayri; Alacacıoğlu, İnci (John Wiley and Sons Inc, 2023)Introduction In multiple myeloma cases, a variety of prognostic parameters have been identified, which contain the Durie-Salmon classification and the international staging system (ISS) that takes the serum ss2 microglobulin ... -
Evaluation of neurological imaging after hematopoietic stem cell transplantation in adults
Sadri, Sevil; Polat, Burcu; Balık Aydın, Berrin; Koçar, Hakan; Gemici, Aliihsan; Beköz, Hüseyin Saffet; Sevindik, Ömür Gökmen; Sargın, Fatma Deniz (Yüzüncü Yıl University Faculty of Medicine, 2022)To investigate the risk factors for, and the incidence of, structural abnormalities in brain imaging among hematopoetic stem cell transplant (HSCT) patients and to correlate these findings with physical examinations. This ... -
First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS)
Sevindik, Ömür Gökmen; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Lippincot Williams & Wilkins, 2022)Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS) is a rare paraneoplastic syndrome of an underlying plasma cell disorder (PCD).1 Castleman disease (CD), itself, can ... -
Gilteritinib (XOSPATA (R)) in Turkey: Early access program results
Doğu, Mehmet Hilmi; Tekgündüz, Ali İrfan Emre; Deveci, Burak; Korkmaz, Gülten; Cömert, Melda; Sevindik, Ömür Gökmen; Yokuş, Osman; Serin, İstemi (Mattioli 1885, 2023)Background And Objectives: Gilteritinib (XOSPATA (R), Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ... -
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
Ferhanoğlu, Burhan; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhit; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Deveci, Burak; Bekoz, Hüseyin; Sevindik, Ömür Gökmen; Toptaş, Tayfur; Yılmaz, Asu Fergün; Koyun, Derya; Alkış, Nihan; Birtaş Ateşoğlu, Elif (American Society of Hematology, 2022)Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ... -
Ibrutinib as a promising treatment for pulmonary complications due to refractory chronic graft versus host disease
İlhan, Osman; Cengiz Seval, Güldane; Uzay, Ant; Kaya, Emin; Öztürk, Zübeyde Nur; Deveci, Burak; Yavaşoğlu, İrfan; Ural, Ali Uğur; Beköz, Hüseyin Saffet; Ayli, Meltem; Sevindik, Ömür Gökmen; Civriz Bozdağ, Sinem; Kurt Yüksel, Meltem; Gülbas, Zafer (Elsevier Science Inc, 2020)Introduction: Despite major improvements in allogeneic hematopoetic stem cell transplantation form matched related/ unrelated donor over last decades, chronic graft-versus-host disease (cGVHD) is still the leading cause ...